Project Grant R01AI187223
Award Date 8/11/25
Completion Date 7/31/30
Dollars Obligated $548K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $431,750 Project Grant to Arizona State University (ASU) to develop a safer and more effective vaccine for monkeypox/smallpox. The funding, provided through the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), will support the establishment of a monkeypox skin cast/EIJ mouse model to evaluate the virulence of multiple monkeypox virus strains and assess the efficacy of a novel, highly...
- This $221,105 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) is supporting research to investigate how poxviruses, such as monkeypox, can rapidly diversify their genomes to overcome host immune defenses. The research aims to advance understanding of the mechanisms by which host APOBEC enzymes can both restrict and promote viral evolution, with the goal of informing strategies to...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), awarded a $156,500 Project Grant to the University of Hawaii at Manoa. The funding will support research to establish human 2D and 3D testicular models to elucidate Monkeypox virus (MPXV) tropism and pathogenic mechanisms in the testes. This research aims to provide direct evidence of MPXV infection in human testis, including identifying...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $466,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to New York University School of Medicine. The grant will support research to elucidate the molecular process of orthopox virus entry, including the MPXV and VACV viruses, through a comparative analysis using methods from virology, proteomics, and immunology. The research aims to identify and characterize the interactions...
- This $228,435 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on January 16, 2025. The grant supports research to uncover the mechanisms enabling the cross-species jumps of viruses, such as the SARS-CoV-2 pandemic and monkeypox (mpox) epidemic, focusing on the Myxoma virus (MYXV) as a model system. The research aims to study the evolution and host adaptation of MYXV,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $33,116,067 Cooperative Agreement to the University of California, Irvine (UCI) for the "Allergy and Infectious Diseases Research" program (CFDA 93.855). The award, titled "The UCI Vaccines for Pandemic Preparedness Center (VPPC)", aims to conduct basic and translational research to develop prototype vaccines against emerging viruses. The project will characterize and compare two universal,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,379,954 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The grant, awarded on August 21, 2025, supports research to engineer durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development. The project aims to systematically study the effects of immunogen affinity, valency, adjuvants, vaccine platforms, and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $281,786 to L2 Diagnostics LLC for the development of a safe and effective viral vector-based vaccine to induce both humoral and cellular immune protection against Powassan virus. The goal is to leverage the Modified Vaccinia Ankara vector platform to stimulate robust antibody and T cell responses that...
- This $199,775 Project Grant from the National Science Foundation Division of Environmental Biology will support research at the University of California, Los Angeles to develop models to understand and predict the spread of monkeypox virus. The research will analyze monkeypox virus surveillance data and transmission patterns in both core and non-core populations. Mathematical models will be built to design disease control strategies, such as comparing outcomes from reducing transmission in...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $791,661 to Duke University to develop a vaccine strategy for HIV-1. The key objectives are to optimize a vaccine delivery platform using integrase-defective lentiviral vectors (IDLVs) to persistently express HIV-1 envelope trimers and Gag antigen. The goal is to elicit durable neutralizing antibody and T-cell...